Ivan Marquez-Rodas
Overview
Explore the profile of Ivan Marquez-Rodas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
11270
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martin-Liberal J, Marquez-Rodas I, Cerezuela-Fuentes P, Soria A, Garicano F, Medina J, et al.
Cancer Treat Rev
. 2025 Jan;
133:102886.
PMID: 39879863
The global incidence of metastatic melanoma with BRAF mutations, characterized by aggressive behavior and poor prognosis, is rising. Recent treatment advances, including immune checkpoint inhibitors (ICI) and targeted therapies (TT)...
2.
Amaral T, Nanz L, Higuita L, Ascierto P, Berking C, Munoz Couselo E, et al.
Eur J Cancer
. 2024 Dec;
215:115160.
PMID: 39673834
Background: Over the past decade, PD-1-based immune checkpoint inhibitors (ICI) and targeted therapies (TT) with BRAF and MEK inhibitors transformed melanoma treatment. Both are widely used in the adjuvant setting....
3.
Long G, Larkin J, Schadendorf D, Grob J, Lao C, Marquez-Rodas I, et al.
J Clin Oncol
. 2024 Nov;
43(8):938-948.
PMID: 39504507
Purpose: Nivolumab (NIVO) + ipilimumab (IPI) combination and NIVO monotherapy have demonstrated durable clinical benefit in patients with unresectable/metastatic melanoma. This analysis describes long-term overall survival (OS) with the combination...
4.
Wolchok J, Chiarion-Sileni V, Rutkowski P, Cowey C, Schadendorf D, Wagstaff J, et al.
N Engl J Med
. 2024 Sep;
392(1):11-22.
PMID: 39282897
Background: Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with advanced melanoma. Given...
5.
Weber J, Del Vecchio M, Mandala M, Gogas H, Arance A, Dalle S, et al.
J Clin Oncol
. 2024 Aug;
42(31):3702-3712.
PMID: 39102624
Purpose: In phase III CheckMate 238, adjuvant nivolumab significantly improved recurrence-free survival compared with ipilimumab in patients with resected stage IIIB-C/IV melanoma without a significant difference in overall survival (OS)....
6.
Cerezuela-Fuentes P, Gonzalez-Cao M, Puertolas T, Luis Manzano J, Maldonado C, Yelamos O, et al.
Clin Transl Oncol
. 2024 Jul;
27(1):386-391.
PMID: 38951438
Background: Novel and highly effective drugs for non-melanoma skin cancer (NMSC) improve patient outcomes, but their high cost strains healthcare systems. Spain's decentralized public health system, managed by 17 autonomous...
7.
Marquez-Rodas I, Alvarez A, Arance A, Valduvieco I, Berciano-Guerrero M, Delgado R, et al.
Neuro Oncol
. 2024 Jul;
26(11):2074-2083.
PMID: 38946469
Background: Encorafenib plus binimetinib (EB) is a standard-of-care treatment for advanced BRAFV600-mutant melanoma. We assessed the efficacy and safety of encorafenib plus binimetinib in patients with BRAFV600-mutant melanoma and brain...
8.
Martinez-Riano A, Mosteo L, Molero-Glez P, Marquez-Rodas I, Melero I
Clin Cancer Res
. 2024 Jun;
30(16):3355-3357.
PMID: 38869441
The presence of moieties denoting viral infection is crucial to mount powerful cytotoxic T-cell immune responses acting through innate receptors such as Toll-like receptor 3. For cancer immunotherapy, several safe...
9.
Gonzalez-Cao M, Puertolas T, Luis Manzano J, Maldonado C, Yelamos O, Berciano-Guerrero M, et al.
Clin Transl Oncol
. 2024 May;
26(10):2572-2583.
PMID: 38750345
Background: The development of highly active drugs has improved the survival of melanoma patients, but elevated drug prices place a significant burden on health care systems. In Spain, the public...
10.
Marquez-Rodas I, Munoz Couselo E, Rodriguez Moreno J, Arance Fernandez A, Berciano Guerrero M, Campos Balea B, et al.
Clin Transl Oncol
. 2024 May;
26(11):2841-2855.
PMID: 38748192
Cutaneous melanoma incidence is rising. Early diagnosis and treatment administration are key for increasing the chances of survival. For patients with locoregional advanced melanoma that can be treated with complete...